Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi Consumer Healthcare India Q4 Results 2025 on 21 Feb, 2025: Revenue decreased by 20.53% YoY & profit decreased by 34.66% YoY, profit at ₹44.3 crore and revenue at ₹170.7 crore.

Sanofi Consumer Healthcare India Limited ( ($IN:SANOFICONR) ) just unveiled an update. Sanofi Consumer Healthcare India ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.

The company faced headwinds in the December 2024 quarter (Q4) as it reported a significant decline in earnings.

The company announced its Q4 results after-market hours. Its shares ended 0.4% higher on Thursday at ₹4,759.35 on the BSE.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Meanwhile, USFDA has conducted a current good manufacturing practices (cGMP) inspection at the analytical testing facility of Sitec Labs, wholly owned subsidiary of the Company (Sitec) located in ...